• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Vidora 3mg/0.03mg, 84 tablets — Made in Spain — Free Delivery

    Vidora 3mg/0.03mg, 84 tablets — Made in Spain — Free Delivery


    Brand: Laboratorios Leon Farma
    Product Code: Vidora
    Availability: In Stock
    $47.29
    Add to Cart

    Product description 

    Vidora film-coated tablets are indicated for oral contraception.

    Compound

    1 blister contains 28 tablets (21 yellow active tablets and 7 white placebo tablets).
    Active ingredients: drospirenone, ethinylestradiol;
    1 yellow coated tablet contains drospirenone 3.0 mg and ethinyl estradiol 0.03 mg;
    Excipients: lactose, corn starch, corn starch, crospovidone Plasdone XL-10 crospovidone Plasdone XL, povidone K-30, polysorbate 80, magnesium stearate, Opadry yellow (polyethylene glycol, polyvinyl alcohol, titanium dioxide (E 171), talc, iron oxide yellow ( E172)).
    1 white coated tablet (placebo) contains:
    Excipients: lactose, povidone K-30, magnesium stearate, Opadry II white (polyvinyl alcohol (hydrolyzed part), titanium dioxide (E 171), macrogol 3350, talc (E 553b)).

    Contraindications

    Combined oral contraceptives (COCs) should not be used if you have any of the conditions listed below. If any of the following diseases appears for the first time while taking COCs, the preparation should be stopped immediately.
    • venous thrombosis (deep vein thrombosis, pulmonary embolism) at present or in history;
    • arterial thrombosis (eg myocardial infarction) in history or the presence of prodromal events (eg angina pectoris and transient ischemic attack);
    • history of stroke.
    Presence of severe or multiple risk factors for arterial thrombosis:
    • diabetes mellitus with vascular symptoms;
    • severe arterial hypertension;
    • severe dyslipoproteinemia;
    • hereditary or acquired tendency to venous or arterial thrombosis, including resistance to activated protein C (APC), antithrombin III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
    • history of pancreatitis if associated with severe hypertriglyceridemia;
    • a history of severe liver disease until liver function tests return to normal;
    • severe renal failure or acute renal failure;
    • a history of liver tumors (benign or malignant);
    • known or suspected tumors dependent on sex hormones (for example, tumors of the genital organs or mammary glands);
    • vaginal bleeding of unknown etiology;
    • migraine with a history of focal neurological symptoms;
    • hypersensitivity to any active substance or any of the excipients;
    • known or suspected pregnancy.

    Mode of application

    Route of administration: oral administration.
    With the correct use of combined oral contraceptives (COCs), the failure rate is about 1% per year. If tablets are missed or taken incorrectly, the failure rate may increase.
    The tablets must be taken every day at the same time, if necessary with a small amount of liquid, in accordance with the order indicated on the blister pack.
    Tablets are taken continuously. One tablet is taken daily for 28 consecutive days. Taking pills from each next pack begins the day after taking the last pill from the previous pack.

    Application features

    pregnant
    Contraindicated.
    Children
    The preparation is indicated for use as prescribed by a doctor only after the onset of stable menstruation.
    Drivers
    A study of the effect of the preparation on the ability to drive vehicles and work with mechanisms has not been conducted. In women using COCs, there was no effect on the ability to drive vehicles and work with mechanisms.

    Overdose

    By this time, there is no experience of an overdose of drospirenone / ethinyl estradiol. Based on the general experience with the use of combined oral contraceptives, symptoms that can be observed with an overdose of active tablets are distinguished: nausea, vomiting, and in young girls - slight bleeding from the vagina. There are no antidotes and further treatment should be symptomatic.

    Side effects

    Emotional lability, headache, abdominal pain, acne, breast pain, breast enlargement, dysmenorrhea, metrorrhagia, weight gain.

    Interaction

    To establish a possible interaction with preparations that are prescribed simultaneously with COCs, it is recommended to read the instructions for use of this preparation.
    The use of contraceptive steroids may affect the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and kidney function, plasma levels of proteins (carriers), for example, corticosteroid-binding globulins, and lipid / lipoprotein fractions, parameters of carbohydrate metabolism, as well as parameters of coagulation and fibrinolysis. In general, these changes remain within normal limits. Drospirenone causes an increase in plasma renin activity and plasma aldosterone levels through negligible antimineralocorticoid activity.

    Storage conditions

    Keep out of the reach of children at a temperature not exceeding 25°C.
    Shelf life - 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017